Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Mon, 14 Sep 2015 12:00:00 GMT ~ Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study
[PR Newswire] - PARIS, Sept. 14, 2015 /PRNewswire/ -- Sanofi announced today that the LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 diabetes treated with insulin glargine with or without metformin. The fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with insulin glargine 100 Units/mL. Overall, the fixed-ratio combination had a safety profile reflecting those of insulin glargine 100 Units/mL and lixisenatide.
Wed, 29 Jul 2015 11:00:00 GMT ~ Sanofi Announces that First LixiLan Phase III Study Met Primary Endpoint
[PR Newswire] - PARIS, July 29, 2015 /PRNewswire/ -- Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL. Overall, the fixed-ratio combination had a safety profile reflecting those of lixisenatide and insulin glargine 100 units/mL.
no recent news found *********************************************************
$ZLDPF charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$ZLDPF company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/ZLDPF/company-info Ticker: $ZLDPF OTC Market Place: Grey Market CIK code: not found Company name: Zealand Pharma A/S Incorporated In:
Business Description:
$ZLDPF share structure
## source: otcmarkets.com
Market Value: $412,355,476 a/o Jun 10, 2015 Shares Outstanding: 22,870,520 a/o Dec 18, 2011 Float: Not Available Authorized Shares: Not Available Par Value: Not Available
Zealand Pharma A/S
Smedeland 36
Glostrup
Copenhagen, 2600
Denmark
Phone: 45 88 77 36 00
Fax: 45 88 77 38 98
Website: http://zealandpharma.com
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide medicines in Denmark. It offers Lyxumia (Lixisenatide), a once-daily prandial GLP-1 receptor agonist for the treatment of type 2 diabetes. The company is also developing Lantus (LixiLan), which is in Phase III clinical trials for the treatment of type 2 diabetes; Danegaptide that is in Phase II clinical trials to treat cardiac reperfusion injuries; and Elsiglutide, a GLP-2 receptor agonist, which is in Phase IIb clinical trials for the treatment of chemotherapy-induced diarrhea in patients with colorectal cancer. In addition, it is developing ZP4207 that is in Phase I clinical trials to treat hypoglycemia in diabetes; and ZP2929, a dual acting glucagon/GLP-1 peptide receptor agonist, which is in Phase I clinical trials for the treatment of diabetes and/or obesity. The company has license agreements and partnerships with Sanofi S.A., Helsinn Healthcare S.A., Boehringer Ingelheim International GmbH, and Eli Lilly. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.